** Shares of cannabinoid drug developer Incannex Healthcare
rise ~82% to $7.66 premarket
** Company says its experimental therapy being tested to treat generalized anxiety disorder (GAD) significantly reduced severity of anxiety symptoms in a mid-stage study
** GAD is a mental health disorder characterized by excessive, persistent and unrealistic worry about everyday things
** The therapy uses a psychedelic compound called psilocybin
** The study was conducted in 73 patients for a period of 7 weeks - IXHL
** Company has planned a follow-up mid-stage study to be conducted at multiple sites in U.S. and UK
** Up to last close, stock down 56% in the last 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Comments